Sales growth is a continuing trend allowing BDA to generate consistent and recurring revenue, with the company expecting its market share to grow.
BDA has a strong cash balance of over $9.2M (at March 31st 2021) and in the march quarter spent $1.3M, less than the $1.87M in revenue it brought in, so the company looks well-funded for the coming months at current rates of revenue and spending.
For more information read: BDA Records Highest Ever Monthly Sales of Medical Cannabis Products
Its share of the market should also increase with the introduction of new products.
BDA attributes its current growth to its Australia wide clinical study to test the efficacy of MediCabilis TM when prescribed for conditions including anxiety, insomnia, and Post Traumatic Stress Disorder (PTSD).
It can also be attributed to ongoing engagement and strong relationships with approved prescribers, educational initiatives with physicians and healthcare professionals.
As a vertically integrated developer, distributor and marketer of plant-based natural medicines, including medicinal cannabis, health products and cosmetic solutions, they are ideally positioned to comb the globe for the highest quality, most effective natural medicines and health products.
BOD Australia (BOD) is an Australian Company publicly listed on the ASX (ASX:BDA), focused on beauty, health and natural medicine to uncover and pioneer the latest innovations worldwide across the healthcare, supplement and cosmetic sectors.
They are currently undergoing Phase 1 trials which will determine the safety, tolerability and pharmacokinetics of its proprietary “ECs315” CBD extract, in partnership with Swiss herbal extracts company Linnea.